Alzheimer's disease (AD) is a neurodegenerative disorder and is known to commence with the progressive amyloid deposition in the brain. Amyloid deposition supposedly occurs between 10-15 years
before the emergence of symptoms such as memory loss.
Researchers at University of Zurich have shown that Aducanumab, a human monoclonal antibody,results in almost complete clearance of the brain amyloid plaques in the study group patients.
This impressive clinical study is a great step forward in treating AD.